Medication Optimization for ADHD: MOVA study. Implementation and evaluation of double-blind placebo-controlled titration in clinical practice<br>

Phase 4

Completed

• Conditions: ADHD; attention-deficit/hyperactivity disorder; 10012562

• Registration Number: NL-OMON46942
• Lead Sponsor: Vrije Universiteit

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 140

Inclusion Criteria

children between the age of 6 and 12 with a DSM-based ADHD diagnosis, with a clinical indication to start pharmacological therapy with short-acting methylphenidate

Exclusion Criteria

- counter-indication for the start-up of methylphenidate (e.g. cardiac problems)
- treated with MPH in the last 4 weeks.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary outcome measures are:<br /><br>-number of placebo and non-responders detected<br /><br>-ADHD symptoms measured with questionnaires<br /><br>-side effects measured with questionnaires</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The secondary outcome measures are:<br /><br>-satisfaction of parents, teachers and therapists on the titration method<br /><br>-symptoms of CD and ODD, social-emotional functioning</p><br>